Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has announced the suspension of trading for its common stock and related stock futures/options starting October 30, 2025, until the listing change date, due to electronic registration changes and cancellations stemming from a corporate spin-off.
📊 [Key Disclosure Details & Financial Figures]
- Disclosure Title: Trading Suspension and Lifting of Suspension
- Target Security: Samsung Biologics Common Stock
- Trading Suspension Date: Starting October 30, 2025
- Trading Resumption Date (Lift Date): Listing Change Date
- Reason for Trading Suspension: Electronic registration changes and cancellations due to corporate spin-off
- Governing Rules: Article 153 of the KOSPI Market Listing Regulations
- Other Reference Items (Derivatives Market): If stock futures and options on the underlying equity are listed, trading of those derivatives will be suspended simultaneously.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verifying Trading Suspension Enforcement and Confirmation of Future Listing Change Date
This disclosure provides notice regarding the trading suspension schedule for the company’s common stock and related derivatives to facilitate electronic registration changes and cancellations required by the corporate spin-off.
It is essential to check the suspension start date (October 30, 2025) and monitor official announcements regarding the finalized listing change date, which will mark the resumption of trading.
Relevant details can be verified in Korea Exchange (KRX) market announcements and subsequent disclosures regarding the listing change.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
